These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6758986)

  • 21. Residual C-peptide production in type I diabetes mellitus. A comparison of different methods of assessment and influence on glucose control.
    Sjöberg S; Gunnarsson R; Ostman J
    Acta Med Scand; 1983; 214(3):231-7. PubMed ID: 6362338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of repeated courses of hyperbaric oxygenation in treatment of insulin-dependent diabetes mellitus].
    Dedov II; Abusuev SA; Muslimova ZZ; Dreval' AV
    Probl Endokrinol (Mosk); 1994; 40(2):25-8. PubMed ID: 8197085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-peptide in the natural history of type 1 diabetes.
    Palmer JP
    Diabetes Metab Res Rev; 2009 May; 25(4):325-8. PubMed ID: 19267337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twenty-four hour urinary C-peptide and fasting plasma C-peptide as indicators of metabolic control in 83 insulin dependent diabetic patients.
    Yoo HJ; Hartling SG; Binder C
    Korean J Intern Med; 1987 Jul; 2(2):196-200. PubMed ID: 3154831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic control, residual insulin secretion and self-care behaviours in a defined group of patients with type 1 diabetes.
    Wikblad K; Montin K; Wibell L
    Ups J Med Sci; 1991; 96(1):47-61. PubMed ID: 1897062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-peptide/creatinine ratio in early morning urine as an indicator of residual B-cell function in insulin-dependent diabetes.
    Sasaki N; Miyamoto S; Niimi H; Nakajima H
    Acta Paediatr Jpn; 1991 Jun; 33(3):375-80. PubMed ID: 1785335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remission phase, endogenous insulin secretion and metabolic control in diabetic children.
    Knip M; Puukka R; Käär ML; Akerblom HK
    Acta Diabetol Lat; 1982; 19(3):243-51. PubMed ID: 6756005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of i.v. tolbutamide on alpha- and beta-cell secretion in type I diabetes].
    Verga S; Donatelli M; Cerasola G; Sinagra D; Inglese CG; Terrizzi C
    Minerva Endocrinol; 1984; 9(3):339-42. PubMed ID: 6398400
    [No Abstract]   [Full Text] [Related]  

  • 29. Improved counter-regulatory hormonal and symptomatic responses to hypoglycemia in patients with insulin-dependent diabetes mellitus after 3 months of less strict glycemic control.
    Liu D; McManus RM; Ryan EA
    Clin Invest Med; 1996 Apr; 19(2):71-82. PubMed ID: 8697673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic elastase-1 in stools, a marker of exocrine pancreas function, correlates with both residual beta-cell secretion and metabolic control in type 1 diabetic subjects.
    Cavalot F; Bonomo K; Perna P; Bacillo E; Salacone P; Gallo M; Mattiello L; Trovati M; Gaia E
    Diabetes Care; 2004 Aug; 27(8):2052-4. PubMed ID: 15277440
    [No Abstract]   [Full Text] [Related]  

  • 31. Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide.
    Björk E; Berne C; Karlsson FA
    Diabetes Care; 1998 Mar; 21(3):427-30. PubMed ID: 9540027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Endogenous insulin reserve in juvenile diabetics as a criterion for therapy].
    Ritterman I; Doron M; Karp M; Laron Z
    Harefuah; 1974 Jul; 87(2):50-3. PubMed ID: 4605655
    [No Abstract]   [Full Text] [Related]  

  • 33. Honeymoon period in insulin-dependent diabetes mellitus.
    Heinze E; Thon A
    Pediatrician; 1983-1985; 12(4):208-12. PubMed ID: 6400451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
    J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
    Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes.
    Koga M; Murai J; Saito H; Kasayama S
    Diabetes Care; 2010 Feb; 33(2):270-2. PubMed ID: 19846794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Islet-cell antibodies and endogenous insulin secretion in Sudanese diabetic children.
    Elamin A; Omer MI; Tuvemo T
    Diabetes Res Clin Pract; 1992 May; 16(2):91-6. PubMed ID: 1600856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group.
    Diabetes; 1988 Nov; 37(11):1574-82. PubMed ID: 2903105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proinsulin/C-peptide ratio, glucagon and remission in new-onset Type 1 diabetes mellitus in young adults.
    Schölin A; Nyström L; Arnqvist H; Bolinder J; Björk E; Berne C; Karlsson FA;
    Diabet Med; 2011 Feb; 28(2):156-61. PubMed ID: 21219422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of duration of type 2 diabetes mellitus on insulin secretion.
    Zangeneh F; Arora PS; Dyck PJ; Bekris L; Lernmark A; Achenbach SJ; Oberg AL; Rizza RA
    Endocr Pract; 2006; 12(4):388-93. PubMed ID: 16939949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.